Marketing attribution: a case study playbook for healthcare and life sciences
The anatomy of a marketing attribution engagement that worked — what we tried, what we killed, and what we would repeat. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install marketing attribution has to reflect that reality from day one.
Names removed, numbers preserved. This is a real marketing attribution engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.
Week one: diagnosis. The stated problem was "not enough leads". The actual problem was picking a model to defend a budget instead of to learn, which had been masked by inbound velocity that peaked two quarters earlier.
Weeks two to three: rebuild the target list from scratch and re-cut the trigger. Marketing attribution works when you cannot allocate spend against a number you don't trust; the client had drifted away from that first principle.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Marketing attribution is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Weeks four to six: live at 20% of previous volume, quality bar raised. Attribution model reconciled to closed-won moved every week, though absolute numbers stayed modest.
Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.
What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.
The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing marketing attribution properly rather than half-heartedly across three vendors.
Frequently asked questions
Measurement · healthcare — answered
- Does marketing attribution work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- How long until the case study company saw results?
- The metric moved in week four; the absolute number caught up around week ten.
- What did the client stop doing?
- Running old tools on autopilot and confusing volume with progress.
- What did the client keep doing?
- The Monday plan, the Friday review, and the weekly attribution model reconciled to closed-won readout.
- Is this case study repeatable?
- The process is repeatable; the numbers depend on category, team, and starting point.
- What is the healthcare specific pitfall with marketing attribution?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under measurement · healthcare